Vinayak Ramanath, MD
Nephrology · Lagrange, GANPI 1356571079
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,162 of the $25,838 with a category attached, or 85.8%. Bayer accounts for 90.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $13,341 and has fallen 96.6% since, to $452 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $187.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$23K
- AstraZeneca$802
- Baxter Healthcare$273
- Travere Therapeutics, Inc.$174
- Amgen$173
- Mallinckrodt Hospital Products Inc.$142
- plus $982 from 18 others
Across 237 payments — averaging $12,780 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.2M
- Vertex$854K
- AstraZeneca$527K
- Alnylam Pharmaceuticals Inc.$150K
- Boehringer Ingelheim$140K
- Merck$49K
- plus $110K from 8 others
What the payments were for
- Consulting fees$820%
- Speaking & faculty fees$22,16286%
- Travel & lodging$1911%
- Food & beverage$3,07112%
- Education$3321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 34 | $23,292 |
| AstraZeneca(2 entities) | 25 | $802 |
| Baxter Healthcare | 7 | $273 |
| Travere Therapeutics, Inc. | 21 | $174 |
| Amgen(2 entities) | 5 | $173 |
| Mallinckrodt Hospital Products Inc. | 3 | $142 |
| Novartis | 6 | $120 |
| Akebia Therapeutics Inc | 6 | $120 |
| Valeritas, Inc. | 1 | $90 |
| GSK | 5 | $82 |
| Amarin Pharma, Inc. | 1 | $81 |
| Novo Nordisk | 4 | $63 |
| Medtronic | 1 | $61 |
| Fresenius USA Marketing, Inc. | 3 | $51 |
| Ardelyx, Inc. | 3 | $51 |
| OPKO Pharmaceuticals, LLC | 3 | $45 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Cormedix Inc. | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$22,534
- FARXIGA$227
- Renal - Non Product Related$102
How this compares
$25,838 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 258 | $201,810 |
| KerendiaFinerenone | 144 | $132,079 |
| JardianceEmpagliflozin | 63 | $59,660 |
| LokelmaSodium Zirconium Cyclosilicate | 32 | $18,782 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $11,710 |
| Sevelamer Carbonate | 43 | $6,700 |
| Losartan Potassium | 183 | $1,666 |
| Nifedipine ErNifedipine | 57 | $1,576 |
| Hydralazine Hcl | 75 | $915 |
| Midodrine Hcl | 25 | $908 |
| Allopurinol | 71 | $899 |
| Calcitriol | 48 | $751 |
| Amlodipine Besylate | 135 | $725 |
| Ondansetron Hcl | 23 | $657 |
| Telmisartan | 16 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $802 | $220,592290 claims |
| BayerKerendia | $23,292 | $132,079144 claims |
| Boehringer IngelheimJardiance | $23 | $59,66063 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Lagrange
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
- Rajendran AlappanColumbus$87K
- William PaxtonLawrenceville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.